Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
Date:8/9/2012

NDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share information)(Unaudited)Three Months EndedSix Months EndedJune 30, June 30,2012201120122011Revenue:Product sales and royalties

$  13,453$  11,008$  23,575$  15,801  License, collaboration and other

10,2316,32318,05812,829Total revenue

23,68417,33141,63328,630Operating costs and expenses:  Cost of goods sold

7,2038,14015,91011,403  Research and development

33,20132,27068,28662,446  General and administrative

10,26811,18520,68222,912  Impairment of long-lived assets

--1,675-Total operating costs and expenses

50,67251,595106,55396,761Loss from operations

(26,988)(34,264)(64,920)(68,131)Non-operating income (expense):  Interest income 

6305291,262961  Interest expense

(7,931)(2,570)(12,264)(5,155)  Other income (expense), net

97(16)757118Total non-operating expense

(7,204)(2,057)(10,245)(4,076)Loss before provision for income taxes

(34,192)(36,321)(75,165)(72,207)Provision for income taxes

9360217208Net loss

$ (34,285)$ (36,381)$ (75,382)$ (72,415)Basic and diluted net loss per share

$
(0.30)$
(0.32)$
(0.66)$
(0.65)Weighted average shares used in computingbasic and diluted net loss per share

114,649114,153114,590111,430NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(In thousands)(Unaudited)Three Months EndedSix Months EndedJune 30, June 30,2012201120122011Comprehensive Loss

$ (34,862)$ (36,433)$ (74,899)$ (72,617)NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Six Months Ended June 30,20122011Cash flows from operating activities:Net loss 

$ (75,382)$(72,415)Adjustments to reconcile net loss to net cash used in operating activities:Non-cash interest expense on
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... , May 19, 2013  The non-surgical ... temperature radiofrequency (RF) energy is effective in control ... reduces the need for medication 10 years post-procedure, ... today at the Digestive Disease Week (DDW) meeting ... . "The sustained improvement ...
(Date:5/18/2013)... 2013 Although colonoscopy exams prevent many colon ... sensitive method for detecting colorectal cancers 2 , the ... 3 . EndoChoice ® Inc. today unveiled research ... the accuracy of this procedure and greatly reduces the ... discussing these clinical trial results and featuring the Fuse ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3
(Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
(Date:5/19/2013)... 19, 2013 Americans live closer to ... newest American Veterinary Medical Association (AVMA) U.S. Pet Ownership ... owners consider their dog a member of the family, ... as much five years earlier. , According to the ... the national income dedicated to pets has increased every ...
(Date:5/19/2013)... Vegas, Nevada (PRWEB) May 19, 2013 ... agency , is proud to announce the launch it's ... Awards at the MGM Grand on 5/19/2013. Consumers traveling ... all new special pricing available on VegasHotelEscapes.com's website. Travelers ... that they beat any competitors price. , Vegas Hotel ...
(Date:5/19/2013)... Passages Malibu, the leading non-12 step, holistic, and ... the launch of a “Sobriety, Health, and Wellness” survey ... “We are always looking for new ways to engage ... regarding sobriety, what’s working for people, and what isn’t,” ... Passages Addiction Treatment Centers located in Malibu and ...
(Date:5/19/2013)... 19, 2013 HealthEconomics.Com , the ... pleased to unveil a new and exciting service: HE-Xpo: ... a powerful array of real-time communication tools to expand ... and abroad. , HE-Xpo is powered by OnStream ... look and feel of being at a physical trade ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... team at Brunel University to help people ridden on wheelchair to ... a day. // ,Presently patients are asked to ... program may soon change all that. It requires only a standard ... ,This would enable doctors to build up information on ...
... The Phase II Clinical Trial conducted by a cancer institute ... for kidney cancer with the help of bevacizumab and erlotinib[1], ... effective and may help in prolonging patient's survival. ... treat, especially once it has started to spread to other ...
... a drug containing parts of diptheria toxin as a way ... //cell of patients suffering from advanced melanoma (Skin Cancer) ... trial to test the drug denileukin diftitox (also known as ... seven patients with stage IV disease experienced significant regression or ...
... Mahathir Mohamad suffered a heart attack Thursday and was admitted ... ,Mahathir, 81, had complained of mild chest pains ... Care Unit (CCU) of the National Heart Institute, the hospital ... agency. ,Mahathir had coronary artery bypass surgery in ...
... software used by doctors, AMA President, Dr Mukesh Haikerwal, ... software packages is expanding rapidly in Australia but the ... of standardised testing of clinical software may create potential ... is calling for a national regulatory framework to standardise ...
... novel method of measuring the risk of heart disease, ... their level of affluence, which also contributes to heart ... often eliminated while studying the risk factors and now ... the inclusion of new parameters, to decide the patients ...
Cached Medicine News:Health News:Pain Tracked By 3D Computer Map 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 3Health News:Diptheria Toxin And Interleukin2 Help Killing Melanoma Tumour Cells 2
Phaco Chopper, double ended; a combination of a modified MicroFinger and a pointed "quick chop" tip, in titanium...
5mm from bend to tip 0.3x2.0mm Tip, Oblong 2 Sided Straight, at 45 degrees; In Titanium...
Angled 40 Degrees, 0.6x0.8 Elliptical Tip; in Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
Medicine Products: